Tags

Type your tag names separated by a space and hit enter

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
Ann Rheum Dis. 2020 07; 79(7):988-990.AR

Authors+Show Affiliations

Research Unit, Sociedad Española de Reumatologia, Madrid, Madrid, Spain.Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Aragón, Spain.Rheumatology, Complejo Hospitalario de Vigo Hospital Xeral, Vigo, Galicia, Spain.Rheumatology, Hospital Universitario Insulsar Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain.Rheumatology, Hospital Universitario Marqués de Valdecilla Servicio de Medicina Interna, Santander, Cantabria, Spain.Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain.Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain jalvarogracia@gmail.com.No affiliation info available

Pub Type(s)

Letter

Language

eng

PubMed ID

32503857

Citation

Sanchez-Piedra, Carlos, et al. "Clinical Features and Outcomes of COVID-19 in Patients With Rheumatic Diseases Treated With Biological and Synthetic Targeted Therapies." Annals of the Rheumatic Diseases, vol. 79, no. 7, 2020, pp. 988-990.
Sanchez-Piedra C, Diaz-Torne C, Manero J, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79(7):988-990.
Sanchez-Piedra, C., Diaz-Torne, C., Manero, J., Pego-Reigosa, J. M., Rúa-Figueroa, Í., Gonzalez-Gay, M. A., Gomez-Reino, J., & Alvaro-Gracia, J. M. (2020). Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Annals of the Rheumatic Diseases, 79(7), 988-990. https://doi.org/10.1136/annrheumdis-2020-217948
Sanchez-Piedra C, et al. Clinical Features and Outcomes of COVID-19 in Patients With Rheumatic Diseases Treated With Biological and Synthetic Targeted Therapies. Ann Rheum Dis. 2020;79(7):988-990. PubMed PMID: 32503857.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. AU - Sanchez-Piedra,Carlos, AU - Diaz-Torne,Cesar, AU - Manero,Javier, AU - Pego-Reigosa,José M, AU - Rúa-Figueroa,Íñigo, AU - Gonzalez-Gay,Miguel A, AU - Gomez-Reino,Juan, AU - Alvaro-Gracia,Jose M, AU - ,, Y1 - 2020/06/05/ PY - 2020/05/12/received PY - 2020/05/21/revised PY - 2020/05/22/accepted PY - 2020/6/7/pubmed PY - 2020/6/26/medline PY - 2020/6/7/entrez KW - arthritis, rheumatoid KW - autoimmune diseases KW - autoimmunity KW - lupus erythematosus, systemic KW - spondylitis, ankylosing SP - 988 EP - 990 JF - Annals of the rheumatic diseases JO - Ann Rheum Dis VL - 79 IS - 7 SN - 1468-2060 UR - https://www.unboundmedicine.com/medline/citation/32503857/Clinical_features_and_outcomes_of_COVID_19_in_patients_with_rheumatic_diseases_treated_with_biological_and_synthetic_targeted_therapies_ L2 - http://ard.bmj.com/lookup/pmidlookup?view=long&pmid=32503857 DB - PRIME DP - Unbound Medicine ER -